Laurus Lab Gets CDSCO Panel Nod To Manufacture and Market Sodium Phenylbutyrate Powder
New Delhi: Noting that urea cycle disorder is a very rare disease and there are unmet medical needs in the country, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has given its nod to Laurus Lab to manufacture and market Sodium Phenylbutyrate powder.
However, this approval is subject to the condition that the firm should conduct a Phase IV clinical trial for which Phase IV clinical trial protocol is to be submitted to CDSCO within 3 months.
Sodium phenylbutyrate is used together with a proper diet to help treat urea cycle disorders, including carbamyl phosphate synthetase deficiency (CPS), ornithine transcarbamylase deficiency (OTC), or argininosuccinate synthetase (AS).
Sodium phenylbutyrate metabolites allow the kidneys to excrete excess nitrogen in place of urea and coupled with dialysis, amino acid supplements, and a protein-restricted diet, children born with urea cycle disorders can usually survive beyond 12 months. Patients may need treatment for all their life.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.